US General Anesthesia Drugs Market Growth, Trends, Size, Demand, Revenue and Future Outlook

US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Published: Jan 2024 Report ID: PHAR2402 Pages: 1 - 106 Formats*:     
Category : Pharmaceutical
US General Anesthesia Drugs Market Introduction and Overview 

According to SPER Market Research, the US General Anesthesia Drugs Market is estimated to reach USD 3.18 Billion by 2033 with a CAGR of 3.6%.

The report includes an in-depth analysis of the US General Anesthesia Drugs Market, including market size and trends, product mix, applications, and supplier analysis. The purpose of a general anaesthesia medication is to induce and maintain unconsciousness and the lack of pain perception. It essentially involves an inducible condition of unconsciousness combined with a partial or total absence of defensive reflexes. It is taken by inhalation or intravenous means in conjunction with drugs. Some intravenous general anaesthetic medications include propofol, etiomide, and ketamine; inhalation anaesthesia medications include sevoflurane and desflurane. Numerous heart procedures, hip and knee replacement surgeries, cancer surgeries, and gastrointestinal surgeries all include the use of general anaesthesia.

  • 2020: Radio-frequency identification technology was integrated into smart labels for the first time by Fresenius Kabi in 2020. Diprivan (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, the first RFID smart-labeled pharmaceutical, was released in the US.
  • 2020: 2020 saw the US debut of the Propofol Injectable Emulsion, USP, in vials of 20 mL, 50 mL, and 100 mL by Hikma Pharmaceuticals USA Inc.
US General Anesthesia Drugs Market
Market Opportunities and Challenges

Opportunity: Patent expiry of Lusedra Fospropofol disodium, sometimes known as Lusedra, is an intravenous sedative-hypnotic drug. In 2008, the FDA authorised it for use in adult patients undergoing therapeutic or diagnostic procedures as managed anaesthesia care (MAC) sedation. By 2022, this chemical will lose its patent. This molecule's patent expiration will open the door for generic medications to join the US market, which should provide a strong growth opportunity for the major market participants.

Challenge: Dangers of general anaesthesia in young patients and expectant mothers
Regarding the use of sedatives and general anaesthetics in young children and pregnant women, the US FDA released cautions in April 2017. Although the FDA highlighted concerns about the possible dangers associated with repeated or prolonged use, particularly in children under three years old and pregnant women, these medicines are necessary for surgical and stressful treatments in these populations. This prudence could lead to a decline in the adoption of general anaesthesia medications among medical professionals, which could potentially impede the expansion of the market. Healthcare professionals should carefully examine the risks and benefits, taking into account the FDA's cautions that may affect the use of certain medications in particular patient populations.

US General Anesthesia Drugs Market


Market Competitive Landscape
The major key players in the US General Anesthesia Drugs Market are: Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others.

Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2033
 Base year considered 2022
 Forecast period 2023-2033
 Segments covered By Route of Administration, By End User
 Regions covered
Central Region, North Region, South Region
 Companies CoveredAbbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others
COVID-19 Impact on US General Anesthesia Drugs Market
The market for general anaesthesia drugs is predicted to suffer as a result of the COVID-19 pandemic, as healthcare systems would be strained and demand will drop as a result of elective surgery postponement or cancellation. Patients with recent or continuing COVID-19 infections are more likely to experience post-operative problems and death, according to a February 2023 paper published in a review for Medical and Pharmacological Sciences. The use of anaesthesia is further complicated by the impossibility of a safe interval between COVID-19 therapy and surgery, as well as possible drug interactions. However, as delayed elective procedures become more common, the need of anaesthetic medications rises as things gradually get back to normal.

Key Target Audience:
  • Pharmaceutical Companies
  • Hospitals and Clinics
  • Anesthesiologists and Anesthesia Providers
  • Medical Device Companies
  • Government Health Departments
  • Distributors and Suppliers
  • Others
Our in-depth analysis of the US General Anesthesia Drugs Market includes the following segments:
By Route of Administration:
  • Inhalational
  • Intravenous
  • Benzodiazepines
  • Methohexital Sodium
  • By End User:
  • Ambulatory Surgery Centres
  • Hospitals
  • By Region:
  • Central Region
  • North Region
  • South Region
  • Key Topics Covered in the Report:
    • US General Anesthesia Drugs Market Size (FY’2023-FY’2033)
    • Overview of US General Anesthesia Drugs Market
    • Segmentation of US General Anesthesia Drugs Market By Route of Administration (Inhalational, and Intravenous)
    • Segmentation of US General Anesthesia Drugs Market By End User (Ambulatory Surgery Centres, Hospitals)
    • Statistical Snap of US General Anesthesia Drugs Market 
    • Expansion Analysis of US General Anesthesia Drugs Market 
    • Problems and Obstacles in US General Anesthesia Drugs Market
    • Competitive Landscape in the US General Anesthesia Drugs Market
    • Impact of COVID-19 and Demonetization on US General Anesthesia Drugs Market 
    • Details on Current Investment in US General Anesthesia Drugs Market
    • Competitive Analysis of US General Anesthesia Drugs Market 
    • Prominent Players in the US General Anesthesia Drugs Market 
    • SWOT Analysis of US General Anesthesia Drugs Market 
    • US General Anesthesia Drugs Market Future Outlook and Projections (FY’2023-FY’2033)
    • Recommendations from Analyst
    1. Introduction
    1.1. Scope of the report
    1.2. Market segment analysis

    2. Research Methodology
    2.1. Research data source
    2.1.1. Secondary Data
    2.1.2. Primary Data
    2.1.3. SPER’s internal database
    2.1.4. Premium insight from KOL’s
    2.2. Market size estimation
    2.2.1. Top-down and Bottom-up approach
    2.3. Data triangulation

    3. Executive Summary

    4. Market Dynamics
    4.1. Driver, Restraint, Opportunity and Challenges analysis
    4.1.1. Drivers
    4.1.2. Restraints
    4.1.3. Opportunities
    4.1.4. Challenges
    4.2. COVID-19 Impacts of the US General Anesthesia Drugs Market 

    5. Market variable and outlook
    5.1. SWOT Analysis
    5.1.1. Strengths
    5.1.2. Weaknesses
    5.1.3. Opportunities
    5.1.4. Threats
    5.2. PESTEL Analysis
    5.2.1. Political Landscape
    5.2.2. Economic Landscape
    5.2.3. Social Landscape
    5.2.4. Technological Landscape
    5.2.5. Environmental Landscape
    5.2.6. Legal Landscape
    5.3. PORTER’s Five Forces 
    5.3.1. Bargaining power of suppliers
    5.3.2. Bargaining power of buyers
    5.3.3. Threat of Substitute
    5.3.4. Threat of new entrant
    5.3.5. Competitive rivalry
    5.4. Heat Map Analysis

    6. Competitive Landscape
    6.1. US General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type 
    6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in US General Anesthesia Drugs Market 

    7. US General Anesthesia Drugs Market, By Route of Administration (USD Million)
    7.1. US General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-2033
    7.2. Inhalational
    7.2.1. Desflurane
    7.2.2. Isoflurane
    7.2.3. Nitrous Oxide
    7.2.4. Sevoflurane
    7.3. Intravenous
    7.3.1. Benzodiazepines
    7.3.2. Etomidate
    7.3.3. Fentanyl
    7.3.4. Ketamine
    7.3.5. Methohexital Sodium
    7.3.6. Propofol
    7.3.7. Remifentanil
    7.3.8. Others

    8. US General Anesthesia Drugs Market, By End User (USD Million)
    8.1. US General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-2033
    8.2. Ambulatory Surgery Centres
    8.3. Hospitals

    9. US General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)
    9.1. US General Anesthesia Drugs Market Size and Market Share

    10. US General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)
    10.1. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)
    10.2. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)

    11. US General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)
    11.1. US General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)
    11.2. US General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)

    12. US General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)
    12.1. US General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)
    12.2. US General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)
    12.3. Central Region
    12.4. North Region
    12.5. South Region

    13. Company Profile
    13.1. Abbott Laboratories
    13.1.1. Company details
    13.1.2. Financial outlook
    13.1.3. Product summary 
    13.1.4. Recent developments
    13.2. AbbVie
    13.2.1. Company details
    13.2.2. Financial outlook
    13.2.3. Product summary 
    13.2.4. Recent developments
    13.3. Akorn
    13.3.1. Company details
    13.3.2. Financial outlook
    13.3.3. Product summary 
    13.3.4. Recent developments
    13.4. AstraZeneca plc
    13.4.1. Company details
    13.4.2. Financial outlook
    13.4.3. Product summary 
    13.4.4. Recent developments
    13.5. Baxter International Inc.
    13.5.1. Company details
    13.5.2. Financial outlook
    13.5.3. Product summary 
    13.5.4. Recent developments
    13.6. Gilead Sciences, Inc
    13.6.1. Company details
    13.6.2. Financial outlook
    13.6.3. Product summary 
    13.6.4. Recent developments
    13.7. Heritage Pharmaceuticals Inc.
    13.7.1. Company details
    13.7.2. Financial outlook
    13.7.3. Product summary 
    13.7.4. Recent developments
    13.8. Novartis AG
    13.8.1. Company details
    13.8.2. Financial outlook
    13.8.3. Product summary 
    13.8.4. Recent developments
    13.9. Par Pharmaceutical
    13.9.1. Company details
    13.9.2. Financial outlook
    13.9.3. Product summary 
    13.9.4. Recent developments
    13.10. Pfizer Inc.
    13.10.1. Company details
    13.10.2. Financial outlook
    13.10.3. Product summary 
    13.10.4. Recent developments
    13.11. Others 
     
    14. List of Abbreviations

    15. Reference Links

    16. Conclusion

    17. Research Scope

    SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

    The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

    SPER-Methodology-1

    SPER-Methodology-2

    SPER-Methodology-3


    Frequently Asked Questions About This Report
    US General Anesthesia Drugs Market is projected to reach USD 3.18 billion by 2033, growing at a CAGR of 3.6% during the forecast period.
    US General Anesthesia Drugs Market size from 2022. The Market is expected to reach USD 3.18 billion by 2033, at a CAGR of 3.6% during the forecast period.
    US General Anesthesia Drugs Market CAGR of 3.6% during the forecast period.
    US General Anesthesia Drugs Market size is 3.18 billion from 2023 to 2033.
    US General Anesthesia Drugs Market Segment is covered By Form, By Purity, By End User.
    The North America is anticipated to have the highest market share in the US General Anesthesia Drugs Market.
    "The key players in the market include Companies Covered Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others."
    the US FDA released cautions in April 2017. Although the FDA highlighted concerns about the possible dangers associated with repeated or prolonged use.
    Not able to find what you are looking for? Need customization in the existing report?
    Click Here
    PLACE AN ORDER
    • 15% off
       
      $ 2950
    • 20% off
               
      $ 3950
    • 25% off
           
      $ 5150
    Pre-Purchase Inquiry
    SEND AN INQUIRY
    NEED CUSTOMIZATION?
    Request Customization
    CALL OR EMAIL US
    US:
    India:
    Email:
    100% Secure Payment

    SPER American Express
    SPER VISA
    SPER Master Card
    SPER Mestro
    SPER Paypal
    SPER CCAvenues

    Join Our SPER Panel

    Our Global Clients

    Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
    SPER-Astellas Pharma
    SPER-Citi Bank
    SPER-Microsoft
    SPER-EY
    SPER-McKinsey
    SPER-Bain
    SPER-Max-Healthcare
    SPER-DHL
    SPER-SIEMENS
    SPER-IQVIA
    SPER-Pfizer
    SPER-LOREAL
    SPER-Kankar IMRB
    SPER-ITA
    SPER-PWC
    SPER-Sanofi
    SPER-p&g
    SPER-Johnson & Johnson
    SPER-IPSOS
    SPER-Heineken

    SPER

    Market Research

    We are the leading, full-service global market research and consulting company.

    Certificates
    iso-1 iso-1 iso-1 ESOMAR
    Secure Payments
    SPER Payment Options
    Contact HR

     [email protected]

     +91-742-898-5650